DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Table 2 Primary and secondary objectives and endpoints

Objective	Endpoint
Primary objective
Evaluate the long-term safety and tolerability of tezepelumab in patients with severe asthma	Exposure-adjusted incidence of AEs, AESIs and SAEs over 104 weeks
Secondary objective
Assess the long-term effect of tezepelumab on asthma exacerbations in adults and adolescents with severe, uncontrolled asthma, compared with placebo	AAER over 104 weeks^a

All objectives relate to tezepelumab 210 mg Q4W SC
AAER annualized asthma exacerbation rate, AE adverse event, AESI adverse events of special interest, Q4W every 4 weeks, SAE serious adverse event, SC subcutaneously
^aBaseline is week 0 in predecessor study (NAVIGATOR or SOURCE)

ISSN: 1465-993X